BioPharma Credit (BPCR) Competitors GBX 0.92 +0.01 (+0.76%) As of 08:35 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesInsider TradesBuy This Stock BPCR vs. NBMI, WKOF, FWD, BRIG, FWT, ASIZ, MAVT, ESO, CTNA, and DRUMShould you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include NB Global Monthly Income Fund Ltd GBP (NBMI), Weiss Korea Opportunity (WKOF), Forward Partners Group (FWD), BlackRock Income and Growth (BRIG), Foresight Technology VCT (FWT), Aberforth Split Level Income ZDP 2024 (ASIZ), Momentum Multi-Asset Value Trust (MAVT), EPE Special Opportunities (ESO), Catena Group (CTNA), and Drumz (DRUM). These companies are all part of the "asset management" industry. BioPharma Credit vs. Its Competitors NB Global Monthly Income Fund Ltd GBP Weiss Korea Opportunity Forward Partners Group BlackRock Income and Growth Foresight Technology VCT Aberforth Split Level Income ZDP 2024 Momentum Multi-Asset Value Trust EPE Special Opportunities Catena Group Drumz NB Global Monthly Income Fund Ltd GBP (LON:NBMI) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends. Do institutionals & insiders hold more shares of NBMI or BPCR? 44.3% of NB Global Monthly Income Fund Ltd GBP shares are owned by institutional investors. Comparatively, 21.4% of BioPharma Credit shares are owned by institutional investors. 0.2% of NB Global Monthly Income Fund Ltd GBP shares are owned by insiders. Comparatively, 0.1% of BioPharma Credit shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings and valuation, NBMI or BPCR? BioPharma Credit has higher revenue and earnings than NB Global Monthly Income Fund Ltd GBP. NB Global Monthly Income Fund Ltd GBP is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNB Global Monthly Income Fund Ltd GBPN/AN/AN/A£0.17N/ABioPharma Credit£124.46M0.08£10.42B£0.109.26 Is NBMI or BPCR more profitable? BioPharma Credit has a net margin of 80.20% compared to NB Global Monthly Income Fund Ltd GBP's net margin of 0.00%. BioPharma Credit's return on equity of 8.51% beat NB Global Monthly Income Fund Ltd GBP's return on equity.Company Net Margins Return on Equity Return on Assets NB Global Monthly Income Fund Ltd GBPN/A N/A N/A BioPharma Credit 80.20%8.51%4.98% Is NBMI or BPCR a better dividend stock? NB Global Monthly Income Fund Ltd GBP pays an annual dividend of GBX 9 per share. BioPharma Credit pays an annual dividend of GBX 0.07 per share and has a dividend yield of 7.6%. NB Global Monthly Income Fund Ltd GBP pays out 5,294.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit pays out 70.1% of its earnings in the form of a dividend. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio. Does the media refer more to NBMI or BPCR? In the previous week, NB Global Monthly Income Fund Ltd GBP's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score. Company Overall Sentiment NB Global Monthly Income Fund Ltd GBP Neutral BioPharma Credit Neutral SummaryBioPharma Credit beats NB Global Monthly Income Fund Ltd GBP on 6 of the 10 factors compared between the two stocks. Get BioPharma Credit News Delivered to You Automatically Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPCR vs. The Competition Export to ExcelMetricBioPharma CreditAsset Management IndustryFinancial SectorLON ExchangeMarket Cap£10.45M£1.47B£6.40B£2.56BDividend Yield7.69%4.59%4.32%5.31%P/E Ratio9.264,757.081,779.595,419.53Price / Sales0.081,980.931,354.9597,527.71Price / Cash1.1960.62127.9327.93Price / Book0.011.372.089.03Net Income£10.42B£265.04M£1.23B£5.89B7 Day Performance1.65%0.21%1.10%0.68%1 Month Performance4.17%1.67%3.12%3.26%1 Year Performance2.55%8.69%32.62%186.78% BioPharma Credit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPCRBioPharma CreditN/AGBX 0.93+0.8%N/A+2.7%£10.45M£124.46M9.26N/ANBMINB Global Monthly Income Fund Ltd GBPN/AN/AN/AN/A£41.02MN/A338.24N/AGap UpWKOFWeiss Korea OpportunityN/AGBX 152+1.3%N/A-3.2%£40.03M-£13.72M-645.98N/AFWDForward Partners GroupN/AN/AN/AN/A£39.78M-£22.03M-155.2615High Trading VolumeBRIGBlackRock Income and GrowthN/AGBX 206flatN/A+0.5%£39.48M£2.48M1,785.10N/AFWTForesight Technology VCTN/AGBX 88flatN/AN/A£39.37M-£2.59M-1,051.56375ASIZAberforth Split Level Income ZDP 2024N/AN/AN/AN/A£39.23M£821K-45.18N/AMAVTMomentum Multi-Asset Value TrustN/AN/AN/AN/A£38.97M-£8.39M-459.68N/AESOEPE Special OpportunitiesN/AGBX 142.90+1.3%N/A-3.8%£37.93M£1.87M52,925.93N/AGap DownCTNACatena GroupN/AN/AN/AN/A£36.86M£883.13K-68.46133DRUMDrumzN/AN/AN/AN/A£36.73M£56K-875.00N/AGap UpHigh Trading Volume Related Companies and Tools Related Companies NB Global Monthly Income Fund Ltd GBP Alternatives Weiss Korea Opportunity Alternatives Forward Partners Group Alternatives BlackRock Income and Growth Alternatives Foresight Technology VCT Alternatives Aberforth Split Level Income ZDP 2024 Alternatives Momentum Multi-Asset Value Trust Alternatives EPE Special Opportunities Alternatives Catena Group Alternatives Drumz Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:BPCR) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioPharma Credit Please log in to your account or sign up in order to add this asset to your watchlist. Share BioPharma Credit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
